The FDA has granted Breakthrough Therapy Designation (BTD) to Provention Bio’s (NASDAQ:PRVB) teplizumab (PRV-031) for the prevention or delay of clinical type 1 diabetes in individuals at-risk of developing the disease.
Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.